

RCS

# Evidence-Based Medicine in the curriculum

Tom Fahey Department of General Practice, Division of Population Health Sciences RCSI Medical School



# Outline

- 1. Background EBM
- 2. Competencies required
- 3. Student assessment of EBM competencies
- 4. A case study
- 5. Future developments & requirements



## (1) Background EBM



# Principals of Evidence-Based Medicine

"Conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients"

(Sackett et al 1997)

贻

2 / 4

## Progress in Evidence-Based Medicine

### SUMMARY OF THE ORIGINAL ARTICLE

Evidence-Based Medicine: A New Approach to Teaching the Practice of Medicine

**.** 

Find

Evidence-Based Medicine Working Group

JAMA. 1992;268(17):2420-2425.

A new paradigm for medical practice is emerging. Evidencebased medicine de-emphasizes intuition, unsystematic clinical experience, and pathophysiologic rationale as sufficient grounds for clinical decision making and stresses the examination of evidence from clinical research. Evidencebased medicine requires new skills of the physician, including efficient literature searching and the application of formal rules of evidence evaluating the clinical literature.

See www.jama.com for full text of the original JAMA article.

Commentary by Victor M. Montori, MD, MSc, and Gordon H. Guyatt, MD, MSc

cluding one based on the Users' Guides series<sup>4</sup>); related series in medical and surgical specialties; and enthusiastic uptake by junior faculty (mostly in general medicine), students,

🏄 Start | 🞯 💡 丛 🛒 🥭 🗿 🗷 📝 💽 😭 📀 🤇

Microsoft PowerPoint - [... || 🙆 http://jama.ama-ass...



# The past





## (2) Competencies required



# Steps in EBM?

- Asking- convert clinical puzzle into an answerable question
- Accessing- search to find evidence to the question
- Appraisal- critical evaluating evidence in terms of validity, quantitative value and clinical relevance
- Applying- decide what clinical action is best for your patient



# Mapping evidence to study design

- What is the most appropriate type of study to answer:
  - Diagnostic question (cross sectional study)
  - Prognostic question (cohort study)
  - Therapeutic question (randomised controlled trial)



### Assessment of study design





# Hierarchy of evidence



- Cohort study
- Case-control study
- Cross-sectional study
- Ecological study
- Case series



Home > Comment > BMJ 2008;336(7650):924 (26 April), doi:10.1136/bmj.39489.470347.AD

This Article Extract FREE Analysis PDF Respond to this article Alert me when this article is cited Alert me when responses are posted Alert me when a correction is posted View citation map Services Email this article to a friend Find similar articles in BMJ Find similar articles in ISI Web of Science Find similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Read articles citing this article Citing Articles via ISI Web worldwide of Science (29) Citing Articles via Google Scholar Google Scholar Articles by Guyatt, G. H

Search for Related Content

PubMed PubMed Citation

Articles by Guyatt, G. H

BMJ 2008;336:924-926 (26 April), doi:10.1136/bmj.39489.470347.AD

Rating quality of evidence and strength of recommendations

### GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

Gordon H Guyatt, professor<sup>1</sup>, Andrew D Oxman, researcher<sup>2</sup>, Gunn E Vist, researcher<sup>2</sup>, Regina Kunz, associate professor<sup>3</sup>, Yngve Falck-Ytter, assistant professor<sup>4</sup>, Pablo Alonso-Coello, researcher<sup>5</sup>, Holger J Schünemann, professor<sup>6</sup>, for the GRADE Working Group

<sup>1</sup> Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada L8N 3Z5, <sup>2</sup> Norwegian Knowledge Centre for the Health Services, PO Box 7004, St Olavs Plass, 0130 Oslo, Norway, <sup>3</sup> Basel Institute of Clinical Epidemiology, University Hospital Basel, Hebelstrasse 10, 4031 Basel, Switzerland, <sup>4</sup> Division of Gastroenterology, Case Medical Center, Case Western Reserve University, Cleveland, OH 44106. USA. 5 Iberoamerican Cochrane Center, Servicio de Epidemiología Clínica y Salud Pública (Universidad Autónoma de Barcelona), Hospital de Sant Pau, Barcelona 08041, Spain, <sup>6</sup> Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy

Correspondence to: G H Guyatt, CLARITY Research Group, Department of Clinical Epidemiology and Biostatistics, Room 2C12, 1200 Main Street, West Hamilton, ON, Canada L8N 3Z5 guyatt@mcmaster.ca

Guidelines are inconsistent in how they rate the quality of evidence and the strength of recommendations. This article explores the advantages of the GRADE system, which is increasingly being adopted by organisations

#### Summary points

Failure to consider the guality of evidence can lead to misguided recommendations; hormone replacement therapy for post-menopausal women provides an instructive example

High quality evidence that an intervention's desirable effects are clearly greater than its undesirable effects, or are clearly not, warrants a strong recommendation

#### What's new

- Last 7 days
- Past weeks
- Current print issue
- Rapid responses

### Latest blogs

- Can the rich save the world?
- The day that human nature changed
- Being critical
- Eating Es
- BMJ in the news
- Who are the Philistines now?
- Richard Lehman's journal blog
- Swine flu blogs

### See also

- Endgames: Cough and breathlessness not responding to inhalers (27 May 2009)
- News: Inadequate data mean UK nations are failing to learn from each other (26 May 2009)
- Editorials: Prevalence of variant CJD in the UK (21 May 2009)
- News: UK urges more flexibility in criteria for flu pandemic alerts (21 May 2009)
- Endgames: An elderly woman with weight loss and diarrhoea (20 May 2009)

### Find BMJ on:

iGoogle	Latest from BMJ
iGoogle	BMJ simple search



Listen to the

latest DTB

The latest medical

news

in your specialty

in your language





# Steps in EBM?

- Asking- convert clinical puzzle into an answerable question
- Accessing- search to find evidence to the question
- Appraisal- critical evaluating evidence in terms of validity, quantitative value and clinical relevance
- Applying- decide what clinical action is best for your patient

5	1	/ 1	9	۲	65%	-		<b></b>	Find	
	 				·		1.1			

		Author: Ref:				
www.cebm.net		Description		Numbers		
	Patients					
	<b>T</b> ntervention					
Question	Comparator					
	Outcomes	2		CER (%)	IER (%)	
sal	<b>R</b> andomized				<u>.</u>	
Appraisal	<b>A</b> scertainment					
A	Measures					
nes	RDifference	CER – EER				
Outcomes	RRR	RD/CER				
ō	NNT	1/RD				

Clinical Bottom-line:

Further Actions:



# Steps in EBM?

 Asking- convert clinical puzzle into an answerable question

Accessing- search to find evidence to the question

- Appraisal- critical evaluating evidence in terms of validity, quantitative value and clinical relevance
- Applying- decide what clinical action is best for your patient



# Primary and secondary literature

- Primary sources are original research publications
- Secondary sources are publications that analyze, synthesize and summarize the evidence
- Can you think of any examples?



# Implementation of research evidence



	www.pubmed.gov					
All Databases	PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books					
Search PubMed	for Go Clear Advanced Search					
About Entrez	Limits Preview/Index History Clipboard Details					
Text Version	To get started with PubMed, enter one or more search terms.					
Entrez PubMed Overview Help   FAQ	Search terms may be <u>topics</u> , <u>authors</u> or <u>journals</u> .					
Tutorials New/Noteworthy 🔊 E-Utilities	NLM/NCBI H1N1 Flu Resources: H1N1 Flu Info					

PubMed Services

Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries Special Queries LinkOut My NCBI

#### **Related Resources**

Order Documents NLM Mobile NLM Catalog NLM Gateway TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central

### U.S. Info • Newest 2009 H1N1 Flu Outbreak Sequences Things You Can Do 🕨 Citations recently added to PubMed Plan & Prepare + International Info > MedlinePlus (consumer health information) Enviro-Health Links HHS.gov CDC.gov The NIH Public Access Policy May Affect You Does NIH fund your work? Then your manuscript must be made available in PubMed Central How? If you publish in one of these journals, they will take care of the whole process. If you publish anywhere else, deposit the manuscript in PubMed Central via one of the options described at publicaccess.nih.gov. Note: Other funding organizations, including HHMI, Wellcome Trust and the MRC also require papers to be made freely available through PMC.

Published

PubMed is a service of the <u>U.S. National Library of Medicine</u> that includes over 18 million citations from MEDLINE and other life science journals for biomedical articles back to 1948. PubMed includes links to full text articles and other related resources.

Write to the Help Desk <u>NCBI | NLM | NIH</u> <u>Department of Health & Human Services</u> <u>Privacy Statement | Freedom of Information Act | Disclaimer</u>



Release Notes 8 October: Changes with Issue 4, 2008... More

#### About The Cochrane Library | Disclaimer | Help

ClinicalE	.viuci		Contraction of the second				
Conditions	Subscribe	Resources	About us	Contact u	s Contribute		
<i>linical Evidence</i> is one o forming treatment decis			resources for	05 January 2009 Log out			
atest updated rev	views			News Feeds	& Email Alerts		
Panic disorder (updated)	) =	Postpartum haemorrha	age:	Get your upd	ates via RSS		
Wrinkles (updated)		prevention (updated)					
Raynaud's (primary) (up	#	Deliberate self-harm an suicide (updated)	nd attempted	Clinical Evide	ence Userguide		
COPD (updated)	*	Chronic pancreatitis (u	pdated)				
Fungal toenail infection:	s (updated) 👘	Acute cholecystitis (upd		Maj Cinica	The Clinical Evidence Userguide, available in		
		Summary of all update			over a dozen languages (now including Finnish), features illustrations an examples of how to get		
Editorial			ieternier divisietee	Liser	the most out of our site.		
There is consensus that							
prevent microvascular co its role in prevention of c							
has been less clear. Sev	veral recent studie	s shed light	Provent in	Articles and I	Research section		
on this issue, and our Ed		w this f how, when,			t independent research on		

### Our methods

The systematic reviews in Clinical

### Consultancy reviews

0

Evidence-based Databases in Medicine

Charles Young, Editor of Clinical Evidence discusses evidence-based information in medicine

### ABCDEFGHIJKLMNOPQKSIUVWXTZ Browse by category

### Deep vein thrombosis (DVT)

Expand All Collapse All

Deep vein thrombosis (DVI)	
Тор	You are viewing a DynaMed summary. Use of DynaMed indicates acceptance of DynaMed Terms of Use Limitations of DynaMed are contained in search within this summary, click Expand All, and then Edit - Find (Ctrl-F) in your brow
General Information (including ICD-9/-10 Codes)	Deep vein thrombosis (DVT) Updated 2008 Sep 09 01:11 PM: case presentation of anomaly of inferior vena cava resulting in clot of lumbar vein (N Engl J Med 2008 Sep 4)
Causes and Risk Factors	women with 0-1 risk factors might be at low risk for recurrence after 6 months of anticoagulation (CMAJ 2008 Aug 26) ACOG Practice Bulletin 84 on prevention of deep vein thrombosis and pulmonary embolism (National Guideline Clearinghouse 2008 Aug 25)
Complications and Associated Conditions	Related Summaries:
History	<ul> <li><u>Pulmonary embolism (PE)</u></li> <li><u>D-dimer testing for venous thromboembolism</u></li> </ul>
Physical	<ul> <li><u>HRT and venous thromboembolism</u></li> <li><u>Anticoagulation</u> for general information</li> </ul>
Diagnosis	<ul> <li>Low-molecular-weight heparin (LMWH) for treatment of venous thromboembolism</li> <li>Perioperative DVT Prophylaxis</li> </ul>
Prognosis	<ul> <li><u>DVT prophylaxis in medical inpatients</u></li> </ul>
Treatment	General Information (including ICD-9/-10 Codes)
Prevention and Screening	Causes and Risk Factors
References including Reviews and Guidelines	<u>Complications and Associated Conditions</u> <u>History</u>
Patient Information	<ul> <li><u>Physical</u></li> <li>Diagnosis</li> </ul>
Acknowledgements	Prognosis
Send Comment to Editor	Treatment
	<ul> <li>Prevention and Screening</li> <li>References including Reviews and Guidelines</li> </ul>
	<ul> <li><u>Patient Information</u></li> <li><u>Acknowledgements</u></li> </ul>



# Steps in EBM?

- Asking- convert clinical puzzle into an answerable question
- Accessing- search to find evidence to the question
  - Appraisal- critical evaluating evidence in terms of validity, quantitative value and clinical relevance
- Applying- decide what clinical action is best for your patient

### Evidence-Based Medicine: Online Library Access

- 📩 Evidence Based Medicine; Introduction & Summary
- 🕑 CCHE Users' Guides to Evidence-Based Practice
- 📩 The Cochrane Library Summary
- 🔁 Finding The Evidence: A Cochrane Exercise
- 📩 Finding The Evidence: A PubMed Exercise
- 🕑 Finding The Evidence: A PubMed Tutorial
  - PubMed: Simple search
  - PubMed: Searching for an author
  - PubMed: Author and subject search
  - 🐵 PubMed: Using MeSH terms
- 🔁 Helping patients to make informed decisions about treatment
- log Putting it into Practice: Practical Application of EBM in General Practice
- Library Session : Finding the evidence in PubMed and Cochrane
- 🕑 Accessing "Clinical Evidence"

### Evidence-Based Medicine: Powerpoint Presentations

- Introduction to Evidence-Based Medicine
- Clarifying the Clinical Question
- 🐻 Diagnostic Test
- 💽 Therapy
- Prognosis
- Clinical Prediction Rules
- 🐻 Fagan Nomogram

### Evidence-Based Medicine: Camtasia Modules

- Introduction
- 🔄 Clarifying The Clinical Question
- Diagnosis: Quantitative Aspects & Clinical Prediction Rules
- 🗉 Therapy
- 🗉 Prognosis

### Evidence-Based Medicine will be examined in MCQ & OSCE



# Steps in EBM?

- Asking- convert clinical puzzle into an answerable question
- Accessing- search to find evidence to the question
- Appraisal- critical evaluating evidence in terms of validity, quantitative value and clinical relevance
- Applying- decide what clinical action is best for your patient



### (3) Assessment of EBM competencies

- Linkage to real clinical problems
- Viewed and assessed in the same way as clinical competencies
  - MCQ
  - OSCE
  - Portfolio



 $You \cdot are \cdot aware \cdot of \cdot a \cdot risk \cdot score \cdot (FRAMO) \cdot for \cdot fracture \cdot in \cdot elderly \cdot women \cdot based \cdot on \cdot their \cdot age \cdot (>80 years), \cdot weight \cdot (<60 kg), \cdot strength \cdot (able \cdot to \cdot rise \cdot 5 \cdot times \cdot independently) \cdot and \cdot past \cdot history \cdot of \cdot fragility \cdot fracture.$ 

 $\label{eq:constraint} The `Table `summarizes `her `risk `in `relation `to `scoring `2 `or `more `from `the `FRAMO `questions. \P$ 

 $(1) \cdot Formulate \cdot a \cdot clinical \cdot question \cdot for \cdot this \cdot clinical \cdot scenario \cdot \cdot (4 \cdot mark \, s) \P$ 

Population	Intervention	Comparison	Outcomea
Elderly-women at	FRAMO risk 2-4	FRAMO risk 0-1	Hip fracture ¶
risk-of-	ſ	1	1
fragility/osteoporosis-	ſ	1	1
fracture	ſ	1	1
¶	ſ	1	1 T
(1·mark)¤	(1·mark)¤	(1·mark)¤	(1·mark)¤

(2)·You·are·aware·that·in·similar·groups·of·patients·the·risk·of·hip·fracture·is·about· 2.5%;·risk·of·fragility·fracture·10%·and·all·cause·mortality·is·5.5%·over·the·following· two·years.·Using·the·nomogram·and·the·information·in·the·Table·estimate·the·risk·of· (1)·hip·fracture;·(2)·other·fragility·fracture·and·(3)·all·cause·mortality·for·Mrs·Moore· over·the·next·two·years·based·on·her·FRAMO·risk·score·(3·marks)¶

 $Calculates \cdot appropriate \cdot post \cdot test \cdot probabilities \cdot for \cdot each \cdot outcome \P \\ \P$ 

Hip·fracture·5.6% → →	<b>→</b>	<b>→</b>	-+	<b>→</b>	<b>-</b>	-+	(1·mark)¶
Other fragility fracture 20.4%	<b>→</b>	<b>-</b>	-+	-+	-+		(1·mark)¶
All·cause mortality 12.7% →	-	-+	-	-+	-+	-	(1 mark)
ſ							
(3)·What·type·of·study·design·i	s·FRA]	MO·bas	ed on?	(1·marl	P(2		
1							
$Cohort \cdot study \rightarrow \rightarrow \rightarrow$	-•	<b>→</b>	-+	-+	-+	-	(1·mark)¶
¶							
(4)·Name·an·alternative·definiti	ion∙of∙t	he FRA	MO·ris	sk∙funct	ion?·(1·	mark)	ſ
¶							
Clinical·prediction·rule 🛛 🗕	<b>→</b>	-+	-+	-+	-+	-	(1·mark)¶
ſ							
(5)·Do·you·think·an·x·ray·of·he	r∙hips∙i	s∙indica	ted, exp	plain∙yo	ur·reas	oningí	?·(1·mark)¶

	🕑 Prodigy		
4	GPortfolio		
	Guidelines for GPortfolio assignment submission		
	🔁 GPortfolio Background Info		
	Evidence-Based Medicine (EBM)		
	Glossary of EBM Terms		
	Model Answers		
	🔁 Diagnosis		
	🔁 Therapy		
	🔁 Prognosis		
	🔁 Ethical Issues in Primary Care		
	🔁 Medication Review		
	🔁 Referral Letter		
	🔀 Background to Reflective Account		
	Assignment Templates		
	GP EBM 1 Diagnosis		
	GP EBM 2 Therapy		
	W GP EBM 3 Prognosis		
	Ethical Dilemma		
	W Medication Review		
	👿 Clinical Encounter Sheet		
	W Referral Letter		
	W Record of Achievement		
	👿 GP Tutor Student Assessment Form		
	👿 ATP GP Student Assessment Form		
	👿 Student Evaluation of GP Tutor, ATP & Department		
	😿 Reflective Account		
	Assignment Uploads Two other documents, both assessments completed and signed off by your GP		
	Tutor and ATP Tutor, are to be delivered by hand to the Department of General Practice.		
	Practice.		
} 🗾 🛒 🧶 🖸 🕱 깨 🗿 🌚 🥝	2 Microsoft Office Pow   Image: http://vle.rcsi.ie - Co	<b>*</b>	<b>***</b> **



### (4) A case study



# Bell's palsy



- Paralysis of VII (facial) cranial nerve
- Cause not known
- Inflammation of nerve
- Herpes Simplex or Varicella Zoster virus may play a role



# Enigmatic smile or incomplete recovery from Bell's Palsy?





# **Treatment options**



•Corticosteroid treatment-

- Salinas, R et al. Corticosteroids for Bell's Palsy. Three RCTs, 117 patients. Inconclusive
- Antiviral treatment-
  - Sipe et al Aciclovir for Bell's Palsy. August 2001 Two trials, 200 patients. Data sparsely reported, findings contradictory



		Author:		Ref:		
www	w.cebm.net	Description		Numbers	;	
	Patients	Patients	with B	ell's Pa	alsy	
	<b>T</b> ntervention	Corticost	eroids			
Question	Comparator	Anti-viral therapy				
		•	CER			
	Outcomes					
sal	Randomized				<u></u>	
pprais	<b>A</b> scertainment					
Ap	Measures					
nes	RDifference	CER – EER				
tcon	RRR	RD/CER				
OU	NNT	1/RD				

Ŧ

Clinical Bottom-line:

Further Actions:



# Randomised Controlled Trial (RCT) Factorial Design

	Prednisolone 50 mg/day 10 days	Placebo
Aciclovir 2g/day 10 days	Both	Aciclovir only
Placebo	Prednisolone only	Neither



### **Results**



Figure 2. Patients Who Had a Full Recovery at 3 Months and 9 Months, According to Study Group.

#### The NEW ENGLAND JOURNAL of MEDICINE

#### ORIGINAL ARTICLE

### Early Treatment with Prednisolone or Acyclovir in Bell's Palsy

Frank M. Sullivan, Ph.D., Iain R.C. Swan, M.D., Peter T. Donnan, Ph.D., Jillian M. Morrison, Ph.D., Blair H. Smith, M.D., Brian McKinstry, M.D., Richard J. Davenport, D.M., Luke D. Vale, Ph.D., Janet E. Clarkson, Ph.D., Victoria Hammersley, B.Sc., Sima Hayavi, Ph.D., Anne McAteer, M.Sc., Ken Stewart, M.D., and Fergus Daly, Ph.D.

#### ABSTRACT

#### BACKGROUND

From the Scottish School of Primary Care (F.M.S.), Community Health Sciences (P.T.D., F.D.), and Dental Health Services Research Unit (J.E.C.), University of Dundee, Dundee; the Department of Otolaryngology (I.R.C.S.) and the Division of Community Based Sciences (J.M.M., S.H.), University of Glasgow, Glasgow; the Department of General Practice and Primary Care (B.H.S., A.M.) and the Health Economics Research Unit (L.D.V.), University of Aberdeen, Aberdeen; Community Health Sciences (B.M., V.H.) and the Department of Clinical Neurosciences (R.J.D.), University of Edinburgh, Edinburgh; and St. John's Hospital, National Health Service Lothian, Livingston (K.S.) all in the United Kingdom. Address reprint requests to Dr. Sullivan at the Scottish School of Primary Care, Mackenzie Bldg., University of Dundee, Kirsty Semple Way, Dundee DD2 4BF, United Kingdom, or at f.m.sullivan@chs.dundee.ac.uk.

N Engl J Med 2007;357:1598-607. Copyright © 2007 Massachusetts Medical Society. Corticosteroids and antiviral agents are widely used to treat the early stages of idiopathic facial paralysis (i.e., Bell's palsy), but their effectiveness is uncertain.

#### METHODS

We conducted a double-blind, placebo-controlled, randomized, factorial trial involving patients with Bell's palsy who were recruited within 72 hours after the onset of symptoms. Patients were randomly assigned to receive 10 days of treatment with prednisolone, acyclovir, both agents, or placebo. The primary outcome was recovery of facial function, as rated on the House–Brackmann scale. Secondary outcomes included quality of life, appearance, and pain.

#### RESULTS

Final outcomes were assessed for 496 of 551 patients who underwent randomization. At 3 months, the proportions of patients who had recovered facial function were 83.0% in the prednisolone group as compared with 63.6% among patients who did not receive prednisolone (P<0.001) and 71.2% in the acyclovir group as compared with 75.7% among patients who did not receive acyclovir (adjusted P=0.50). After 9 months, these proportions were 94.4% for prednisolone and 81.6% for no prednisolone (P<0.001) and 85.4% for acyclovir and 90.8% for no acyclovir (adjusted P=0.10). For patients treated with both drugs, the proportions were 79.7% at 3 months (P<0.001) and 92.7% at 9 months (P<0.001). There were no clinically significant differences between the treatment groups in secondary outcomes. There were no serious adverse events in any group.

#### CONCLUSIONS

In patients with Bell's palsy, early treatment with prednisolone significantly improves


## Application of evidence

- Steroids clearly best option
- What about anti-viral therapy?
  - May relate to:
    - Aetiology
    - Severity

۱d

Sullivan, et al<sup>4</sup> Hato, et al<sup>2</sup> Setting Primary and secondary care University hospital departments only Blinding Double-blind Single-blind (patients only, assessors unblinded) Randomisation Independent, automated Envelope method telephone randomisation service Prednisolone with or without Intervention Prednisolone with or without aciclovir vs placebo valaciclovir (no placebo-only group) House-Brackmann scale Primary outcome measure Yanagihara scoring system Number randomised 296 551 Number analysed in 496 (90%) 221 (75%) results (%)

#### Table: Differences between studies

assessment confound interpretation of their results, and these flaws have been noted before.<sup>5</sup> Most surprisingly, Hato and colleagues neglect to mention the other trial of valaciclovir published in 2007, also from Japan,<sup>3</sup> which did not show any advantage of adding valaciclovir.

Their enthusiasm for antivirals is based on their aetiological prejudices rather than firm evidence. The association between Bell's palsy and viral reactivation does not prove causation, and until better data supporting the use of antivirals becomes available University of Edinburgh, Edinburgh EH4 2XU, UK (RJD, BM); University of Dundee, Dundee, UK (FS); University of Aberdeen, Aberdeen, UK (BS); and University of Glasgow, Glasgow, UK (JM)

- Hato N, Murakami S, Gyo K. Steroid and antiviral treatment for Bell's palsy. Lancet 2008; 371: 1818–20.
- 2 Hato N, Yamada H, Kohno H, et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo-controlled study. Otol Neurotol 2007; 28: 408–13.
- 3 Kawaguchi K, Inamura H, Abe Y, et al. Reactivation of herpes simplex virus type 1 and varicella-zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope 2007; 117: 147–56.
- 4 Sullivan FM, Swan IR, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Duly and the Al Society Access of the Alexandree Alexandree

the clinical are the same ZSH is ofter palsy witho studies. ZSH 8–28% of cas Since VZV

palsy and t than that of that ZSH s different t Therefore, with ZSH whereas Su did not. B 1000 mg/c VZV (the 3000 mg/da expected to patients with

The most treatment of of the facial of sequelae contractures is high in pa The prognos palsy is ger without me



### Evidence needs to be:

- Complete
- Up-to-date
- Based on the highest form of evidence (RCT for therapeutic interventions)
- Methodologically sound
- Applicable



# (4) Future developments & requirements



### The future

Knowledge summaries

 Decision support for health professionals

Decision aids for patients



# Implementation of research evidence





### A UK Google for guidelines



Published Online April 30, 2009 DI:10.1016/S0140-6736(09)60830-8 ment Lancet 2009; 373: 1502

wlins' Viewpoint of NICE see Lancet ed online April 24. 5/S0140-6736(09) 60616-4

Darzi's Next Stage ttp://www.dh.gov. tionsandstatistics/ publicationspolicy dance/DH\_085825 line Comment on development see 9; published online DI:10.1016/S0140-6736(09)60787-X

The UK's National Institute for Health and Clinical Excellence (NICE) has been appraising the evidence and publishing clinical and public health advice for 10 years. Last year, NICE was given a new mandate. As part of his review of the National Health Service (NHS), Ara Darzi tasked the organisation with developing a one-stopshop whereby health-care professionals could readily access reliable and up-to-date advice to inform their daily practice. Enter NHS Evidence.

Launched on April 30, and introduced in a Comment by its Chief Operating Officer, Gillian Leng, NHS Evidence is an ambitious project aimed at creating a Google-like portal through which users-professionals and the public alike—can obtain information ranked in order of quality and relevance. Unlike Google, however, NHS Evidence's ranking will be informed by an independent advisory committee rather than a computer algorithm. Guidanceproducing bodies, such as professional organisations and the UK's Royal Colleges, will be subject to an accreditation process which, if passed, gives them the NHS Evidence seal of approval and their guidance a higher rating.

NHS Evidence's role in adjudicating between different guidelines on the same topic has the potential to encourage better practice in guideline development. As illustrated in a Comment by Jack Hirsh and Gordon Guyatt, published online on April 24, professional bodies can differ substantially in their recommendations. Often this difference is due to bias resulting from conflicting interests of the writing committees. One of the domains that NHS Evidence will assess is the independence of such committees; this is a vital step forward.

The project team is to be applauded for its clearsighted and thorough approach to generating such a long-overdue source of credible advice. Lack of time, inclination, and knowledge of where to start reduce the likelihood that a health-care professional will look for guidance, and the concept of NHS Evidence certainly addresses the issues of time and place. What is needed in addition is an equally broad-reaching encouragement and awareness campaign to help persuade the proverbial horse, having been provided with the water, to drink it. The Lancet



# Computer-based clinical decision support (CDSS)

	ECLINDA- CD	SS
Consultation	<u>A</u>	e
Consultation Details (*)	Profile DOB Sex	
Patient Summary	Import Details: [ALL]	import 4 Previous Searches for this patient
Begin Consultation	Clinical Findings Today	Baseline Details
Edit Consultation     Finish Consultation     Gen Consultation	Vitals Muscular	Date         BP         Chol         Ht         Wt         BMI         Cig         Alc         Wst           20/06/2006         134 / 76         5.65         179.0         45         14.04         0         0         0
Notes *	Cardiovascular Neurological Respiratory Urology	Current Medications
Prescriptions *	Gastro Other	RONALLIN (AMONYCILLIN) CAPS 250MG (AMONYCILLIN) Acute
0	CDSS RESULTS	
Documents (*) Care Protocols (*)	Disease Control Rating	Active Diagnosis 29/03/2006 Low Blood Pressure
d Appointments		
Waiting Room	Suggested Treatment	
Patient Maintenance	New Research	Past Medical History
3 Reports		Family Diabetes
S Communication		
🕼 My Control Panel 🍣	Links	
		CDSS RESULTS



National Collaborating Centre for Women's and Children's Health

## Caesarean section

Clinical Guideline April 2004 Funded to produce guidelines for the NHS by NICE 🚵 File Edit Display Values Window Help Options Analysis



P

😵 Decision Analysis by T	eeAge (DATA) Professional -	[Tree]	
💹 File Edit Display Values	Window Help Options Analysi	is	- 8 ×
	<b>₣</b> ₽   :   <b>/:</b>   0  :  :  :  :  :  :  :  :  :  :  :  :		
	planned vaginal delivery planned vaginal delivery pop per production producti	nemorrhage=p HaemorrhageVD ssterectomy=p HysterectomyVD continence=p IncontinenceVD fection=p InfectionVD M=p MOAVD p Minpay=p Op InjunyVD I=p FITVD A=p FMVD romh=p Thromh VD rth Frocess=uFVDAVD p VD	•
Decision concerning planned mode of delivery <b>pApgarEnCS=0.002</b> <b>pApgarVD=0.022</b> <b>pApgarVD=0.022</b> <b>pBrainEnCS=0.001</b> <b>pBrainEnCS=0.008</b>	pAp pBr pHa pHa pHo pDr pPT pPT pPT pDr uBr uBr	rgency LSCS (+) (+) (******************************	
p Branch CS=0.008 p Breathing ELCS=0.036 p Breathing Eln CS=0.036 p Breathing Eln CS=0.122 p Breathing VD=0.0053 p Blective CS=0.9 p Haemonthage ELCS=0.014 p Haemonthage Eln CS=0.014 p Haemonthage VD=0.009 p Hysterectomy ELCS=0.004 p Hysterectomy Eln CS=0.003 p Hysterectomy VD=0.001 p Incontinence Eln CS=0.158 p Incontinence VD=0.21 p Infection Eln CS=0.084 p Infection Eln CS=0.08 p Infection Eln CS=0.08 p Infection VD=0.035 p MMEI CS=0.00015 p MMVD=0.00015 p MMVD=0.000017	pBr pBr pHa pHy pho pfm pM pOp pFT pFM pDa uBin uBin uBin pBr pBr pBr pBr pBr pBr pBr pBr pBr pBr	<pre>syst=pApgarHCS ain=pBrainBCS eathing=pBreathingECS eathing=pBreathingECS seteretomy=pHysteretomyECS continence=pIncontinenceECS fection=pIncontinenceECS fection=pIncontinenceECS fection=pIncontineCS M=pIntBCS M=pIntBCS aromb=pIncontbECS rthProcess=uPCSECS pElectiveCS engency LSCS pgr=pApgarEnCS sam=pBrainEmCS reathing=pBreathingEnCS reathing=pBreathingEnCS reathing=pBreathingEnCS seteretomy=nHysteretomyEnCS</pre>	

	Com	plications for Moth	ner
Introduction			
	Click on the underlined headings to see more		Utarian Duratura
Frequently	Hysterect	-	Uterine Rupture
Asked Questions	Incontine		Infection
Guestions	Surgical I	<u>)amage</u>	Blood Clots
Complications	Severe Pe	erineal Damage	Delayed Conception
for Mother	Haemorrh	lage	Death of Mother
Complications	Hysterectomy		
for Baby			excessive bleeding, which cannot be controlled with aesarean section. It means future pregnancy will not
	be possible.		
Non-medical			
Benefits			
Special Circumstances			
Circumstances			
Glossary			



Introduction	Complications for Baby	
	Click on the underlined headings to see more	
Frequently	Baby Breathing Difficulties	
Asked Questions	Infant Brain Injury	
Questions	Death of Baby	
Complications	Baby in Poor Condition	
for Mother		
	Baby Breathing Difficulties	
Complications for Baby	The baby relies on its mother for a supply of oxygen while within the womb. It practices breathing movements but the lungs	
lor baby	are filled with fluid. During delivery the fluid is gradually squeezed out of the lungs. With the first breath shortly after delivery the baby is usually ready for independent life. Occasionally babies require some assistance with breathing. In mild cases this	
Non-medical	is called transient tachypnoea of the newborn (TTN). In more severe cases the baby may require assisted breathing with a	
Benefits	ventilator, this is called respiratory distress syndrome (RDS).	
	Vaginal Birth The process of vaginal birth helps to push the liquid out of the baby's lungs, which is beneficial to the baby's breathing at birth.	
Special	Caesarean Section	
Circumstances	Breathing difficulties are increased the earlier the elective section is performed.	
Glossary		

When you have read enough information please click on Section 2 to rate your preferences





When you are finished click 'Delivery Method' to rate your preferences about different types of delivery.





Section 1

2

### .0 healthtalkonline

Search

conditions forums about us news login/register

home



'Favorites 🚱 🔗 🛬 🔟 🔹 📙 🔝 🗱 🕖 🖄

Search...

.0

People's stories: see, hear and read their experiences...

#### Welcome

Healthtalkonline, an award-winning charity website, lets you share in other people's experiences of health and illness. You can watch or listen to videos of the interviews, read about people's experiences and find reliable information about conditions, treatment choices and support.

The information on healthtalkonline is based on qualitative research into patient experiences, led by experts at the University of Oxford. These personal stories of health and illness will enable patients, families and healthcare professionals to benefit from the experiences of others. How to use this site...

Cancer	Heart disease
Nerves & brain	Bones & joints
Mentai health	Pregnancy & children
Living with dying	Carers
Chronic health issues	Living with disability
Intensive care	Medical research

#### News Website of the month - .... Launch of the Osteoporosis ....





Forum

#### **Ovarian Cancer**

Welcome to the Healthtalkonline Forum on Ovarian Cancer. 18/05/2009

hello

20/05/2009



Tell us your story You can help support others by sharing your own experiences



## Conclusions

- EBM core competency for health professionals
  - Finding, appraising and applying evidence
- Requires inter-professional learning
  - Undergraduate
  - Postgraduate (life long learning)
- Synopses and synopses of evidence into the future